Lung histopathological findings in COVID-19 disease–a systematic review
G Pannone, VCA Caponio, IS De Stefano… - Infectious Agents and …, 2021 - Springer
Since December 2019, the global burden of the COVID-19 pandemic has increased rapidly
and has impacted nearly every country in the world, affecting those who are elderly or with …
and has impacted nearly every country in the world, affecting those who are elderly or with …
On the origin of neutrophil extracellular traps in COVID-19
M Pastorek, M Dúbrava, P Celec - Frontiers in Immunology, 2022 - frontiersin.org
Despite ongoing vaccination COVID-19 is a global healthcare problem because of the lack
of an effective targeted therapy. In severe COVID-19 manifesting as acute respiratory …
of an effective targeted therapy. In severe COVID-19 manifesting as acute respiratory …
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial
P Sivapalan, CS Ulrik, TS Lapperre… - European …, 2022 - Eur Respiratory Soc
Background Combining the antibiotic azithromycin and hydroxychloroquine induces airway
immunomodulatory effects, with the latter also having in vitro antiviral properties. This may …
immunomodulatory effects, with the latter also having in vitro antiviral properties. This may …
Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: a systematic review and meta‐analysis
M Rubio‐Rivas, CG Forero… - … : The Journal of …, 2021 - Wiley Online Library
Introduction The results of studies of tocilizumab (TCZ) in COVID‐19 are contradictory. Our
study aims to update medical evidence from controlled observational studies and …
study aims to update medical evidence from controlled observational studies and …
Efficacy of tocilizumab in the treatment of COVID‐19: An umbrella review
MM Rezaei Tolzali, M Noori, P Shokri… - Reviews in Medical …, 2022 - Wiley Online Library
Tocilizumab is an interleukin (IL)‐6 receptor inhibitor that has been proposed as a
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …
Guidelines on the treatment with integrated traditional Chinese medicine and western medicine for severe coronavirus disease 2019
ZY Li, ZJ Xie, HC Li, JJ Wang, XH Wen, SY Wu… - Pharmacological …, 2021 - Elsevier
Abstract Severe Coronavirus Disease 2019 (COVID-19) is characterized by numerous
complications, complex disease, and high mortality, making its treatment a top priority in the …
complications, complex disease, and high mortality, making its treatment a top priority in the …
High-CBD cannabis extracts inhibit the expression of proinflammatory factors via miRNA-mediated silencing in human small intestinal epithelial cells
The incidence of chronic inflammatory disorders and autoimmune diseases is rapidly
growing. To date, the COVID-19 pandemic caused by SARS-CoV-2 has killed over …
growing. To date, the COVID-19 pandemic caused by SARS-CoV-2 has killed over …
Lack of difference in tocilizumab efficacy in the treatment of severe COVID-19 caused by different SARS-CoV-2 variants
Tocilizumab (TOC) is presumed to be an effective and safe treatment for severe COVID-19,
but its usefulness has not been yet investigated for different SARS-CoV-2 variants. This …
but its usefulness has not been yet investigated for different SARS-CoV-2 variants. This …
Duration of SARS-CoV-2 RNA shedding is significantly influenced by disease severity, bilateral pulmonary infiltrates, antibiotic treatment, and diabetic status …
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) ribonucleic acid
(RNA) shedding is an important parameter for determining the optimal length of isolation …
(RNA) shedding is an important parameter for determining the optimal length of isolation …
Should we interfere with the interleukin-6 receptor during COVID-19: what do we know so far?
A Plocque, C Mitri, C Lefèvre, O Tabary, L Touqui… - Drugs, 2023 - Springer
Severe manifestations of COVID-19 consist of acute respiratory distress syndrome due to an
initially local reaction leading to a systemic inflammatory response that results in hypoxia …
initially local reaction leading to a systemic inflammatory response that results in hypoxia …